Delta-8-THCM

Delta-8-THCM
Identifiers
	IUPAC name (6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene;
CAS Number	1451-20-3;
PubChem CID	15114753;
ChemSpider	19975471;
ChEMBL	ChEMBL114082;
Chemical and physical data
Formula	C22H32O2
Molar mass	328.496 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC1=CC2=C([C@@H]3CC(=CC[C@H]3C(O2)(C)C)C)C(=C1)OC;
	InChI InChI=1S/C22H32O2/c1-6-7-8-9-16-13-19(23-5)21-17-12-15(2)10-11-18(17)22(3,4)24-20(21)14-16/h10,13-14,17-18H,6-9,11-12H2,1-5H3/t17-,18-/m1/s1; Key:GRLARWXSTOXAGR-QZTJIDSGSA-N;

Delta-8-THCM (O-Methyl-Δ⁸-THC) is a chemical compound related to phytocannabinoids found in Cannabis. It has been sold as a designer drug, first identified in Sweden in June 2024.^[1] However, it is a known compound which has been well established to almost entirely lack cannabinoid-like effects in mice, rats and monkeys,^[2]^[3] unlike the dimethylheptyl analogue L-759,633 which is a selective agonist for CB₂ and has antiinflammatory but not psychoactive effects.^[4]

References

^ "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.
^ Mechoulam R, Edery H (1973). "Structure-Activity Relationships in the Cannabinoid series.". In Mecoulam R (ed.). Marijuana Chemistry, Pharmacology, Metabolism, and Clinical Effects. New York: Academic Press. pp. 101–136.
^ Compton DR, Prescott WR, Martin BR, Siegel C, Gordon PM, Razdan RK (November 1991). "Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol". Journal of Medicinal Chemistry. 34 (11): 3310–3316. doi:10.1021/jm00115a023. PMID 1659638.
^ Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (February 1999). "Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630". British Journal of Pharmacology. 126 (3): 665–672. doi:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.

[1] "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.

[2] Mechoulam R, Edery H (1973). "Structure-Activity Relationships in the Cannabinoid series.". In Mecoulam R (ed.). Marijuana Chemistry, Pharmacology, Metabolism, and Clinical Effects. New York: Academic Press. pp. 101–136.

[Compton_1991-3] Compton DR, Prescott WR, Martin BR, Siegel C, Gordon PM, Razdan RK (November 1991). "Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol". Journal of Medicinal Chemistry. 34 (11): 3310–3316. doi:10.1021/jm00115a023. PMID 1659638.

[4] Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (February 1999). "Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630". British Journal of Pharmacology. 126 (3): 665–672. doi:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.

[1]

[2]

[3]

[4]

See also

References